Oral factor Xa inhibitors for the long-term management of ACS.

about

Implications of new anticoagulants in primary practice.Novel antiplatelet agents in acute coronary syndrome.Antithrombotic therapy for patients with STEMI undergoing primary PCI.Advances in the Treatment of Stable Coronary Artery Disease and Peripheral Artery Disease.

P2860

Q38073006-BE9C1AF0-578D-439F-AF65-9DCD12E62DA6 Q38257119-B89990A1-14EE-46E7-9A2A-B793D403A6BE Q39147735-D517CD27-CBB9-493F-8D47-A8E704545AFF Q55269457-9B8B8E50-D157-4974-A83B-91743E10BA3C

P2860

Oral factor Xa inhibitors for the long-term management of ACS.

Item

http://www.wikidata.org/entity/Q43594298

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Oral factor Xa inhibitors for the long-term management of ACS.

@en

Oral factor Xa inhibitors for the long-term management of ACS.

@nl

type

Item

label

Oral factor Xa inhibitors for the long-term management of ACS.

@en

Oral factor Xa inhibitors for the long-term management of ACS.

@nl

prefLabel

Oral factor Xa inhibitors for the long-term management of ACS.

@en

Oral factor Xa inhibitors for the long-term management of ACS.

@nl

P1476

Oral factor Xa inhibitors for the long-term management of ACS.

@en

P2093

James W Wisler

http://www.w3.org/2001/XMLSchema#string

Richard C Becker

http://www.w3.org/2001/XMLSchema#string

P2860

RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome

The discovery of (2R,4R)-N-(4-chlorophenyl)-N- (2-fluoro-4-(2-oxopyridin-1(2H)-yl)phenyl)-4-methoxypyrrolidine-1,2-dicarboxamide (PD 0348292), an orally efficacious factor Xa inhibitor

Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulat

Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor

Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

Blood coagulation at the site of microvascular injury: effects of low-dose aspirin

Warfarin, aspirin, or both after myocardial infarction

Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939--an oral, direct Factor Xa inhibitor

P304

392-401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRCARDIO.2012.18

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22348973

http://www.w3.org/2001/XMLSchema#string

Oral factor Xa inhibitors for the long-term management of ACS.

about

P2860

P2860

Oral factor Xa inhibitors for the long-term management of ACS.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698